V117957

DRUG3 trials

Sponsors

Purdue Pharma LP, Imbrium Therapeutics

Conditions

Interstitial Cystitis/Bladder Pain SyndromeOveractive Bladder SyndromePostsurgical Pain Due to Third Molar Extraction

Phase 1

Study of V117957 in Overactive Bladder Syndrome

CompletedNCT06024642

Imbrium TherapeuticsOveractive Bladder Syndrome

Start: 2022-06-30End: 2024-05-21Updated: 2025-06-26

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

CompletedNCT06285214

Imbrium TherapeuticsInterstitial Cystitis/Bladder Pain Syndrome

Start: 2022-05-26End: 2025-01-28Updated: 2026-03-09

Phase 2

An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction

TerminatedNCT01900795

Purdue Pharma LPPostsurgical Pain Due to Third Molar Extraction

Start: 2013-07-31End: 2013-11-30Updated: 2013-12-05